

Titolo:	NIRVANA-1 - Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery
Patologia:	Ovaio
Tipo di Studio:	Interventistico farmacologico
Fase:	2
Principali criteri di inclusione:	Patient with newly diagnosed, a. Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer, b. Histologically confirmed (based on local histopathological findings): • high grade serous or • high grade endometrioid (grade 2 and 3) or • other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation c. At an advanced stage: FIGO stage IIIA to IIIC of the 2018 FIGO classification.
Principali criteri di esclusione:	- Patient with clear cell adenocarcinoma or carcinosarcoma, non-epithelial origin of the ovarian tumor, the fallopian tube or the peritoneal tumor (i.e. germ cell tumors). - Ovarian tumor of low malignant potential (e.g. borderline tumor), or mucinous carcinoma.
Sede e contatti	AO S. Croce e Carle ctc@ospedale.cuneo.it 0171641539